ArticleMemorias do Instituto Oswaldo Cruz2013
Antischistosomal activity of a calcium channel antagonist on schistosomula and adult Schistosoma mansoni worms.
Article in Memorias do Instituto Oswaldo Cruz, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 33 citations in OpenAlex.
- Repurposing drugs to treat trichinellosis: in vitro analysis of the anthelmintic activity of nifedipine and Chrysanthemum coronarium extract.BMC complementary medicine and therapies · 2023Article
- Real-time and automated monitoring of antischistosomal drug activity profiles for screening of compound libraries.iScience · 2022Article
- A Machine Learning Strategy for Drug Discovery Identifies Anti-Schistosomal Small Molecules.ACS infectious diseases · 2021Article
- Parallelized Impedance-Based Platform for Continuous Dose-Response Characterization of Antischistosomal Drugs.Advanced biosystems · 2020Article
- Article
- Anti-schistosomal action of the calcium channel agonist FPL-64176.International journal for parasitology. Drugs and drug resistance · 2019Article
- WIPO Re:Search-A Platform for Product-Centered Cross-Sector Partnerships for the Elimination of Schistosomiasis.Tropical medicine and infectious disease · 2019Article
- Calcium Ion Channels: Roles in Infection and Sepsis Mechanisms of Calcium Channel Blocker Benefits in Immunocompromised Patients at Risk for Infection.International journal of molecular sciences · 2018Review
- Pharmacological and immunological effects of praziquantel against Schistosoma japonicum: a scoping review of experimental studies.Infectious diseases of poverty · 2018Article
- In silico repositioning of approved drugs against Schistosoma mansoni energy metabolism targets.PloS one · 2018Article
- Calcium channel blockade and survival in recipients of successful renal transplant: an analysis of the FAVORIT trial results.International journal of nephrology and renovascular disease · 2018Article
- TRP channels in schistosomes.International journal for parasitology. Drugs and drug resistance · 2016Review
- Does calcium channel blockade have a role in prevention of expression of sepsis in renal transplant recipients?International journal of nephrology and renovascular disease · 2016Review
- Natural products as leads in schistosome drug discovery.Molecules (Basel, Switzerland) · 2015Article
- In silico repositioning-chemogenomics strategy identifies new drugs with potential activity against multiple life stages of Schistosoma mansoni.PLoS neglected tropical diseases · 2015Article
- Activity Profile of an FDA-Approved Compound Library against Schistosoma mansoni.PLoS neglected tropical diseases · 2015Article
- Modulation of mice immune responses against Schistosoma mansoni infection with anti-schistosomiasis drugs: Role of interleukin-4 and interferon-gamma.International journal of health sciencesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Current schistosomiasis control strategies are largely based on chemotherapeutic agents and a limited number of drugs are available today. Praziquantel (PZQ) is the only drug currently used in schistosomiasis control programs. Unfortunately, this drug shows poor efficacy in patients during the earliest infection phases. The effects of PZQ appear to operate on the voltage-operated Ca2+ channels, which are located on the external Schistosoma mansoni membrane. Because some Ca2+ channels have dihydropyridine drug class (a class that includes nifedipine) sensitivity, an in vitro analysis using a calcium channel antagonist (clinically used for cardiovascular hypertension) was performed to determine the antischistosomal effects of nifedipine on schistosomula and adult worm cultures. Nifedipine demonstrated antischistosomal activity against schistosomula and significantly reduced viability at all of the concentrations used alone or in combination with PZQ. In contrast, PZQ did not show significant efficacy when used alone. Adult worms were also affected by nifedipine after a 24 h incubation and exhibited impaired motility, several lesions on the tegument and intense contractility. These data support the idea of Ca2+ channels subunits as drug targets and favour alternative therapeutic schemes when drug resistance has been reported. In this paper, strong arguments encouraging drug research are presented, with a focus on exploring schistosomal Ca2+ channels.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.